The role of DNA ploidy in postoperative management of stage I endometrial cancer

Annals of Oncology

Volumn 19, Issue 7, 2008, Pages 1278-1283

  Mangili, G ^a   Montoli, Serena ^a   De marzi, P ^a   Sassi, I ^a   Aletti, G ^a,a   Taccagni, G ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

Adjuvant treatment; Endometrial cancer; Ploidy; Prognostic factors

Indexed keywords

CISPLATIN; CYCLOPHOSPHAMIDE; DNA; DOXORUBICIN; PACLITAXEL;

ABDOMINAL HYSTERECTOMY; ADULT; ARTICLE; CANCER ADJUVANT THERAPY; CANCER RADIOTHERAPY; CANCER RELAPSE; CANCER STAGING; CANCER SURVIVAL; CLINICAL DECISION MAKING; CONTROLLED STUDY; ENDOMETRIUM CANCER; FEMALE; FOLLOW UP; HIGH RISK PATIENT; HUMAN; LYMPH NODE; MAJOR CLINICAL STUDY; PLOIDY; POSTOPERATIVE CARE; PRIORITY JOURNAL; PROGNOSIS; SALPINGOOOPHORECTOMY; VAGINAL HYSTERECTOMY;

DNA, NEOPLASM; ENDOMETRIAL NEOPLASMS; FEMALE; FOLLOW-UP STUDIES; HUMANS; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM STAGING; PLOIDIES; POSTOPERATIVE CARE; SURVIVAL ANALYSIS; TIME FACTORS; TREATMENT OUTCOME;

EID: 46249122921     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdn041     Document Type: Article

References (28)

1. Maggino T, Romagnolo C, Bandoni F et al. An analysis of approaches to the management of endometrial cancer in North America: A CTF study. Gynecol Oncol 1998; 68: 274-279.
2. Aalders J, Abeler V, Kolstad P, Onsrud M. Postoperative external irradiation and prognostic parameters in stage I endometrial carcinoma: clinical and histopathologic study of 540 patients. Obstet Gynecol 1980; 56(4): 419-427.
3. Creutzberg CL, van Putten WL, Koper PC et al. Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: Multicentre randomized trial. Lancet 2000; 355: 1404-1411.
4. Keys HM, Roberts AJ, Brunetto VL et al. A phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: A Gynecologic Oncology Group study. Gynecol Oncol 2004; 92: 744-751.
5. Lukes AS, Kohler MF, Pieper CF et al. Multivariable analysis of DNA ploidy, p53 and HER-2/neu as prognostic factors in endometrial cancer. Cancer 1994; 73: 2380-2385.
6. Newbury R, Schuerch C, Goodspeed N et al. DNA content as a prognostic factor in endometrial carcinoma. Obstet Gynecol 1990; 76: 251-257.
7. Zaino RJ, Davis ATL, Ohlsson-Wilhelm BM, Brunetto VL. DNA content is an independent prognostic indicator in endometrial carcinoma. Int J Gynecol Pathol 1998; 17: 312-319.
8. Larson DM, Bergs R, Shaw G, Krawisz BR. Prognostic significance of DNA ploidy in endometrial cancer. Gynecol Oncol 1999; 74: 356-360.
9. Susini T, Rapi S, Savino L et al. Prognostic significance of flow cytometric deoxyribonucleic acid index in endometrial carcinoma: comparison with other clinical pathologic parameters. Am J Obstet Gynecol 1994; 170: 527-534.
10. Lundgren C, Auer G, Frankendal B et al. Prognostic factors in surgical stage I endometrial carcinoma. Acta Oncol 2004; 43: 49-56.
11. Gudmundsson TE, Hogberg T, Alm P et al. The prognostic information of DNA ploidy and S-phase fraction may vary with histologic grade in endometrial carcinoma. Acta Oncol 1995; 34: 803-812.
12. Lim P, Aquino-Parson CF, Wong F et al. Low-risk endometrial carcinoma: assessment of a treatment policy based on tumor ploidy and identification of additional prognostic indicators. Gynecol Oncol 1999; 73: 191-195.
13. Mangili G, De Marzi P, Viganò R et al. Identification of high risk patients with endometrial carcinoma. Prognostic assessment of endometrial cancer. Eur J Gynecol Oncol 2002; 23: 216-220.
14. Bênedetti Panici PL, Frigerio L, Sardi J et al. Feasibility and complications of systematic lymphadenectomy in endometrial cancer. Preliminary results of a prospective randomized multicentric clinical trial. Int J Gynecol Cancer 1999; 9(1): 88-89.
15. Creasman WT, Odicino F, Maisonneuve P et al. Carcinoma of the corpus uteri. FIGO 6th Annual Report on the results of treatment in gynaecological cancer. Int J Gynaecol Obstet 2006; 95(1): S105-43.
16. Hedley DW, Friedlander ML, Taylor IW et al. Method for analysis of cellular DNA content of paraffin-embedded pathological material using flow cytometry. J Histochem Cytochem 1983; 31: 1333-1335.
17. Maggi R, Lissoni A, Spina F et al. Adjuvant chemotherapy vs radiotherapy in high-risk endometrial carcinoma: Results of a randomised trial. Br J Cancer 2006; 95(3): 266-271.
18. Mangili G, De Marzi P, Beatrice S et al. Paclitaxel and concomitant radiotherapy in high-risk endometrial cancer patients: Preliminary findings. BMC Cancer 2006; 6: 198.
19. Cox DR. Regression models and life tables. J R Stat Soc 1972; 34: 187-202.
20. Amant F, Moerman P, Neven P et al. Endometrial cancer. Lancet 2005; 366(9484): 491-505.
21. Naumann RW, Coleman RL. The use of adjuvant radiation therapy in early endometrial cancer by members of the Society of Gynecologic Oncologists in 2005. Gynecol Oncol 2007; 105(1): 7-12.
22. Terada K, Mattson D, Goo D, Shimizu D. DNA aneuploidy is associated with increased mortality for stage I endometrial cancer. Gynecol Oncol 2004; 95: 483-487.
23. Susini T, Amunni G, Molino C et al. Ten-year results of a prospective study on the prognostic role of ploidy in endometrial carcinoma. Cancer 2007; 109(5): 882-890.
24. Hogberg T, Fredstorp-Lidebring M, Alm P et al. A prospective population-based management program including primary surgery and postoperative risk assessment by means of DNA ploidy and histopathology. Adjuvant radiotherapy is not necessary for the majority of patients with FIGO stage I-II endometrial cancer. Int J Gynecol Cancer 2004; 14: 437-450.
25. Ackerman I, Malone S, Thomas G et al. Endometrial carcinoma - relative effectiveness of adjuvant irradiation vs therapy reserved for relapse. Gynecol Oncol 1996; 60: 177-183.
26. Mandell LR, Nori D, Hilaris B. Recurrent stage I endometrial carcinoma: results of treatment and prognostic factors. Int J Radiat Oncol Biol Phys 1985; 11(6): 1103-1109.
27. Curran WJ, Whittington R, Peters AJ, Fanning J. Vaginal recurrences of endometrial carcinoma: The prognostic value of staging by a primary vaginal carcinoma system. Int J Radiat Oncol Biol Phys 1988; 15(4): 803-808.
28. Ayhan A, Taskiran A, Celik C et al. Is there survival benefit to adjuvant radiotherapy in high-risk surgical stage I endometrial cancer? Gynecol Oncol 2002; 86: 259-263.